Cargando…

Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure

AIMS: Few biomarkers to evaluate pathophysiological changes in extra‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kagami, Kazuki, Sunaga, Hiroaki, Sorimachi, Hidemi, Harada, Tomonari, Yoshida, Kuniko, Kato, Toshimitsu, Kurosawa, Koji, Kawakami, Ryo, Koitabashi, Norimichi, Iso, Tatsuya, Adachi, Takeshi, Kurabayashi, Masahiko, Obokata, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006713/
https://www.ncbi.nlm.nih.gov/pubmed/33539661
http://dx.doi.org/10.1002/ehf2.13239
_version_ 1783672362273603584
author Kagami, Kazuki
Sunaga, Hiroaki
Sorimachi, Hidemi
Harada, Tomonari
Yoshida, Kuniko
Kato, Toshimitsu
Kurosawa, Koji
Kawakami, Ryo
Koitabashi, Norimichi
Iso, Tatsuya
Adachi, Takeshi
Kurabayashi, Masahiko
Obokata, Masaru
author_facet Kagami, Kazuki
Sunaga, Hiroaki
Sorimachi, Hidemi
Harada, Tomonari
Yoshida, Kuniko
Kato, Toshimitsu
Kurosawa, Koji
Kawakami, Ryo
Koitabashi, Norimichi
Iso, Tatsuya
Adachi, Takeshi
Kurabayashi, Masahiko
Obokata, Masaru
author_sort Kagami, Kazuki
collection PubMed
description AIMS: Few biomarkers to evaluate pathophysiological changes in extra‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive biomarker for liver injury. However, little is known about the potential role of FABP1 as a biomarker for HF. METHODS AND RESULTS: Measurements of serum FABP1 and echocardiography were performed in subjects with compensated HF (n = 162) and control subjects without HF (n = 20). Patients were prospectively followed‐up for a composite outcome of all‐cause mortality or HF hospitalization. Compared with control subjects, levels of FABP1 were elevated in HF patients [7.9 (6.4–11.7) vs. 17.6 (10.4–28.9) ng/mL, P < 0.0001]. There were significant correlations between FABP1 levels and estimated right ventricular systolic pressure and right atrial pressure. During a median follow‐up of 12.0 months, there were 55 primary composite endpoints in the HF cohort. The highest FABP1 tertile was associated with a three‐fold increased risk of the composite outcome compared with the lowest tertile [95% confidence interval (1.46–6.68), P = 0.003], but other conventional hepatobiliary markers did not predict the outcome. After adjusting for age, sex, atrial fibrillation, and N‐terminal pro‐B‐type natriuretic peptide levels, serum FABP1 remained independently associated with the outcome. Adding FABP1 to the model based on clinical factors and N‐terminal pro‐B‐type natriuretic peptide significantly improved the prognostic value (global χ (2) 20.8 vs. 15.5, P = 0.01). CONCLUSION: Serum FABP1 levels are elevated in compensated HF patients, and the magnitude of elevation is independently associated with pulmonary hypertension, right atrial hypertension, and worse clinical outcomes. FABP1 may serve as a new potential biomarker for the assessment of hitherto unrecognized derangement of cardio‐hepatic interaction in HF.
format Online
Article
Text
id pubmed-8006713
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80067132021-04-01 Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure Kagami, Kazuki Sunaga, Hiroaki Sorimachi, Hidemi Harada, Tomonari Yoshida, Kuniko Kato, Toshimitsu Kurosawa, Koji Kawakami, Ryo Koitabashi, Norimichi Iso, Tatsuya Adachi, Takeshi Kurabayashi, Masahiko Obokata, Masaru ESC Heart Fail Original Research Articles AIMS: Few biomarkers to evaluate pathophysiological changes in extra‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive biomarker for liver injury. However, little is known about the potential role of FABP1 as a biomarker for HF. METHODS AND RESULTS: Measurements of serum FABP1 and echocardiography were performed in subjects with compensated HF (n = 162) and control subjects without HF (n = 20). Patients were prospectively followed‐up for a composite outcome of all‐cause mortality or HF hospitalization. Compared with control subjects, levels of FABP1 were elevated in HF patients [7.9 (6.4–11.7) vs. 17.6 (10.4–28.9) ng/mL, P < 0.0001]. There were significant correlations between FABP1 levels and estimated right ventricular systolic pressure and right atrial pressure. During a median follow‐up of 12.0 months, there were 55 primary composite endpoints in the HF cohort. The highest FABP1 tertile was associated with a three‐fold increased risk of the composite outcome compared with the lowest tertile [95% confidence interval (1.46–6.68), P = 0.003], but other conventional hepatobiliary markers did not predict the outcome. After adjusting for age, sex, atrial fibrillation, and N‐terminal pro‐B‐type natriuretic peptide levels, serum FABP1 remained independently associated with the outcome. Adding FABP1 to the model based on clinical factors and N‐terminal pro‐B‐type natriuretic peptide significantly improved the prognostic value (global χ (2) 20.8 vs. 15.5, P = 0.01). CONCLUSION: Serum FABP1 levels are elevated in compensated HF patients, and the magnitude of elevation is independently associated with pulmonary hypertension, right atrial hypertension, and worse clinical outcomes. FABP1 may serve as a new potential biomarker for the assessment of hitherto unrecognized derangement of cardio‐hepatic interaction in HF. John Wiley and Sons Inc. 2021-02-04 /pmc/articles/PMC8006713/ /pubmed/33539661 http://dx.doi.org/10.1002/ehf2.13239 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research Articles
Kagami, Kazuki
Sunaga, Hiroaki
Sorimachi, Hidemi
Harada, Tomonari
Yoshida, Kuniko
Kato, Toshimitsu
Kurosawa, Koji
Kawakami, Ryo
Koitabashi, Norimichi
Iso, Tatsuya
Adachi, Takeshi
Kurabayashi, Masahiko
Obokata, Masaru
Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
title Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
title_full Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
title_fullStr Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
title_full_unstemmed Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
title_short Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
title_sort prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006713/
https://www.ncbi.nlm.nih.gov/pubmed/33539661
http://dx.doi.org/10.1002/ehf2.13239
work_keys_str_mv AT kagamikazuki prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT sunagahiroaki prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT sorimachihidemi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT haradatomonari prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT yoshidakuniko prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT katotoshimitsu prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT kurosawakoji prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT kawakamiryo prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT koitabashinorimichi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT isotatsuya prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT adachitakeshi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT kurabayashimasahiko prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure
AT obokatamasaru prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure